Orionn, a pharmaceutical company, experienced significant growth in its financial performance for the October-September period compared to the previous year. The company’s operating profit increased to 92.9 million euros from 40.7 million euros in the same period a year ago, exceeding analyst forecasts.
A major contributor to this improvement was a 30.7 million euro installment related to the transfer of the insurance portfolio of Orion Pension Foundation’s B section. However, even after adjusting for this item, the result still showed improvement from the previous year.
Turnover for the quarter was 321.1 million euros, higher than the estimated 318.9 million euros and the 294.5 million euros from the previous year. Earnings per share also increased, reaching 0.54 euros per share compared to the expected 0.43 euros.
The board of directors proposed a dividend of 1.62 euros per share for the last fiscal year